For ICU patients that have life-threatening inflammation and infection, the only effective treatment methods are steroids and antibiotics which have harmful side effects or lead to multidrug resistance. AyuVis is harnessing the power of novel small molecules to develop immunotherapies that modulate the body's first line of defense, white blood cells, to fight inflammation and infection with a balanced immune response. They prevent tissue and organ damage, promote new cell growth, and circumvent multi-drug resistance to defeat tough-to-beat bacterial infections. This has been proven in extensive preclinical research and human clinical trials are on the horizon.